Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2015 > Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study

Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study

Read also

Recordati Considers €10.9B CVC Capital Acquisition Offer Before Q1 Close

Recordati Considers €10.9B CVC Capital Acquisition Offer Before Q1 Close

Italian pharma Recordati weighs a €10.9bn acquisition offer from CVC Capital. Discover the details of this major M&A deal ahead of the Q1 2026 close.

Simulations Plus and Pharma Partners Advance AI-Driven Drug Development

Simulations Plus and Pharma Partners Advance AI-Driven Drug Development

Simulations Plus announces strategic partnerships with three pharmaceutical companies to integrate AI into model-informed drug development workflows.

Wave Life Sciences Stock Plummets 50% on Weak Phase I Obesity Trial Data

Wave Life Sciences Stock Plummets 50% on Weak Phase I Obesity Trial Data

Wave Life Sciences' stock crashed 50% after its Phase I obesity trial for WVE-007 showed lower-than-expected weight loss, disappointing investors.

FDA Approves Novo Nordisk's Awiqli®: First Once-Weekly Insulin for T2D

FDA Approves Novo Nordisk's Awiqli®: First Once-Weekly Insulin for T2D

The FDA has approved Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults living with type 2 diabetes to improve A1C.